


### **REMARKS/ARGUMENTS**

Reconsideration and allowance of the present application based on the following remarks are respectfully requested. Applicants have amended the specification to correct a typographical error in the naming of compound 61. The amendment to the specification is supported by the Structure depicted at page 59 of the specification, by the details of the synthesis in Example 10 and by the NMR analysis at the end of Example 10. Claims 1, 3, 19 and 20 have been amended. Claims 5, 7, 9, 11-18 and 21-22 have been withdrawn and amended as being drawn to non-elected subject matter. Claims 2, 4, 6, 8, 10 and 23-24 have been cancelled. Claims 25-29 have been added. Support for the amendments and the new claims may be found throughout the specification, such as at Scheme 9 and Examples 9-10. No new matter has been added.

In response to the Restriction Requirement dated April 4, 2008, Applicants elect Group I (Claims 1-4, 19, 20, 23 and 24). With respect to the required species election, Applicants elect the following species:

5-[4-(2',4'-dimethoxybiphenyl-3-yloxy)-benzyl]-thiazolidine-2,4-dione:



Claims 1, 3, 19, 20 and 25-29 read on the elected compound. As Group 1 was selected, Applicants believe that they are in full compliance with 35 U.S.C. § 121 by selection of this species. Applicants respectfully request rejoinder of the withdrawn method claims upon indication of allowance of claim 1, as these claims include each and every limitation of claim 1.


In view of the foregoing, the claims are now believed to be in form for allowance, and such action is hereby solicited. If any points remain in issue which the Examiner feels may be best resolved through a personal or telephone interview, she is kindly requested to contact the undersigned at the telephone number listed below.

All objections and rejections having been addressed, it is respectfully submitted that the present application is in a condition for allowance and a Notice to that effect is earnestly solicited.

Respectfully submitted,

JONES DAY

By: \_\_\_\_\_

  
John E. Mauk  
Registration No. 54,579  
Direct No. (202) 879-3628

Paul L. Sharer  
Registration No. 36,004  
Direct No. (202) 879-5481

51 Louisiana Ave, N.W.  
Washington, D.C. 20001-2113  
(202) 879-3939 Telephone  
(202) 626-1700 Facsimile

Date: June 4, 2008